Oncotarget

Research Papers:

GBM-associated mutations and altered protein expression are more common in young patients

Sherise D. Ferguson _, Joanne Xiu, Shiao-Pei Weathers, Shouhao Zhou, Santosh Kesari, Stephanie E. Weiss, Roeland G. Verhaak, Raymond J. Hohl, Geoffrey R. Barger, Sandeep K. Reddy and Amy B. Heimberger

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69466-69478. https://doi.org/10.18632/oncotarget.11617

Metrics: PDF 1022 views  |   HTML 1424 views  |   ?  


Abstract

Sherise D. Ferguson1, Joanne Xiu4, Shiao-Pei Weathers2, Shouhao Zhou3, Santosh Kesari5, Stephanie E. Weiss6, Roeland G. Verhaak7, Raymond J. Hohl8, Geoffrey R. Barger9, Sandeep K. Reddy4, Amy B. Heimberger1

1Department of Neurosurgery, Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

2Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

3Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

4Caris Life Sciences, Phoenix, AZ 85040, USA

5Department of Translational Neuro-Oncology and Neurotherapeutics, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA

6Fox Chase Cancer Center, Philadelphia, PA 19111, USA

7Department of Genome Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77054, USA

8Penn State Hershey Cancer Institute, Hershey, PA 17033, USA

9Department of Neurology, Wayne State University, School of Medicine, Karmanos Cancer Center, Detroit, MI 48201, USA

Correspondence to:

Sherise D. Ferguson, email: sdferguson@mdanderson.org

Joanne Xiu, email: JXIU@CARISLS.COM

Keywords: GBM, mutational analysis, DNA sequencing

Received: June 19, 2016     Accepted: August 15, 2016     Published: August 25, 2016

ABSTRACT

Background: Geriatric glioblastoma (GBM) patients have a poorer prognosis than younger patients, but IDH1/2 mutations (more common in younger patients) confer a favorable prognosis. We compared key GBM molecular alterations between an elderly (age ≥ 70) and younger (18 < = age < = 45) cohort to explore potential therapeutic opportunities.

Results: Alterations more prevalent in the young GBM cohort compared to the older cohort (P < 0.05) were: overexpression of ALK, RRM1, TUBB3 and mutation of ATRX, BRAF, IDH1, and TP53. However, PTEN mutation was significantly more frequent in older patients. Among patients with wild-type IDH1/2 status, TOPO1 expression was higher in younger patients, whereas MGMT methylation was more frequent in older patients. Within the molecularly-defined IDH wild-type GBM cohort, younger patients had significantly more mutations in PDGFRA, PTPN11, SMARCA4, BRAF and TP53.

Methods: GBMs from 178 elderly patients and 197 young patients were analyzed using DNA sequencing, immunohistochemistry, in situ hybridization, and MGMT-methylation assay to ascertain mutational and amplification/expressional status.

Conclusions: Significant molecular differences occurred in GBMs from elderly and young patients. Except for the older cohort’s more frequent PTEN mutation and MGMT methylation, younger patients had a higher frequency of potential therapeutic targets.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11617